RNArt

RNArt is a biotechnology company specializing in the design and development of circular RNA (circRNA) therapeutics. Founded by RNA biology pioneer Dr. Thomas Tuschl, the company focuses on leveraging the unique structural properties of circularized RNA to improve the stability and translation efficiency of RNA-based medicines. By overcoming the limitations of traditional linear mRNA, such as rapid degradation and immunogenicity, RNArt aims to create next-generation vaccines and protein replacement therapies. In early 2024, the company was acquired by BioNTech to integrate its proprietary circRNA technology into BioNTech's global portfolio of immunotherapy and infectious disease programs.